As of September 30, 2025, TYRA had cash, cash equivalents and marketable securities of $274.9M. TYRA’s current cash, cash equivalents and ...

CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target ...

The mutational spectrum of fibroblast growth factor receptor 3 (FGFR3) in individuals with achondroplasia. In humans, the mutations associated with achondroplasia patients are mainly located in ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

CARLSBAD, Calif., Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA ...

COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency ...

Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia BioMarin conducted a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety and ...

SEATTLE — A combination of a prodrug derived from C-type natriuretic peptide (CNP) called navepegritide (TransCon CNP) and a prodrug of somatropin, called lonapegsomatropin (Skytrofa), augmented the ...

At the core of achondroplasia's pathology lies the hyperactivation of FGFR3, which impairs not only the growth of long bones but also affects cranial, spinal, and vertebral development.